FARMINGDALE, N.Y., Nov. 7, 2013 /PRNewswire/ — Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today announced financial results for the first quarter of fiscal year 2014 ended September 30, 2013.
First Quarter Fiscal 2014 Financial Results
Revenue for the three months ended September 30, 2013 was $3.1 million, a 33% decrease when compared to $4.6 million for the same period in fiscal 2013. Part of the decrease was attributable to the approximate $363,000 lower revenue from Aesculap and lower stocking sales to international markets as compared to the same quarter in fiscal 2013.
BoneScalpel revenue was $1.3 million, SonaStar revenue was $1.1 million and SonicOne(R) revenue was $469,000 for the first quarter 2014.
There were 36 BoneScalpel units sold or placed during the first quarter fiscal 2014 compared to 57 BoneScalpel units sold or placed during the first quarter of fiscal 2013. BoneScalpel domestic disposable sales increased 74% during the first quarter fiscal 2014 compared to the same period in fiscal 2013, excluding Aesculap.
The Company reported a net loss of $884,002, or ($.12) diluted loss per share, compared to net income of $44,834, or $0.01 earnings per share, in fiscal 2013.
Michael A. McManus, Jr., President and CEO, stated, “This was another quarter for progress for your Company. You will remember our strategy of consigning units in conjunction with purchases of our disposable blade. The result of this formula shows continued high margins and an increase of BoneScalpel units in the U.S. BoneScalpel revenue from disposables increased 74% in the U.S., excluding Aesculap, resulting from an increase of 65% in disposable units from the first quarter of fiscal 2013. Total recurring revenue from disposables increased to 53% of total sales for the quarter. These results are all indicators of growth and surgeons continued acceptance and use of our unique technology. The acceptance of the significant benefits to doctor, patient and hospital are consistently increasing. We expect to see growth across all products and in all markets over the coming quarter.”
“We are excited about the reception we are receiving at prominent trade shows and professional conferences. We are experiencing considerable traffic from both surgeons and potential new distributors. Testimony from prominent surgeons at these meetings is particularly encouraging and has been reported in recent press releases.”
Mr. McManus concluded, “We are executing on our strategy to deliver more predictable revenue streams from high margin sales. We are seeing indications for expected growth across the upcoming quarters.”